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1. Introduction into lipids
Dyslipidemia is a major cardiovascular disease (CVD) risk factor that is fre-
quently encountered in clinical practice, affecting one in three adults (over 30% 
of adult population) in the United States alone [1, 2]. It is generally associated 
with other CVD risk factors including insulin resistance/diabetes, hypertension, 
and central obesity. With the publication of the landmark observational study, the 
Framingham Heart Study, the predictive relationship between hypercholesterolemia 
and coronary heart disease (CHD) was established, where adults with total cho-
lesterol (TC) of >300 mg/dl were 5 times more likely to have CHD, compared with 
those of TC of <200 mg/dl [3]. These findings were further supported by data from 
another landmark study, the Multiple Risk Factor Intervention Trial (MRFIT) that 
clearly demonstrated a graded and strongly positive correlation between TC levels 
and CHD mortality [4]. Subsequently, multiple trials using various lipid-lowering 
agents clearly established CVD benefits from lipid lowering. For example, the Lipid 
Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), using cholestyr-
amine, a bile acid sequestrant, demonstrated that 1% reduction in TC led to 2–3% 
reduction in CHD risk [5]. Similarly, using gemfibrozil, a fibric acid derivative, 
in the Helsinki Heart Study, a 5-year primary prevention trial, there was 34% risk 
reduction in myocardial infarction and sudden cardiac death in the treatment group, 
compared to placebo [6]. With the advent of statins, numerous clinical trials have 
shown CVD benefits with cholesterol-lowering therapy that are above and beyond 
just lowering lipid levels [7]. These findings collectively reinforced the negative 
connotation associated with lipids in general, despite the vital roles lipids play in 
various metabolic processes such as the bi-lipid layer cell membrane, the formation 
of steroid hormones, and bile. In this introductory chapter to our book that addresses 
topical issues of dyslipidemia, we provide an introduction we believe will be useful 
to a wide range of audiences including students, researchers, and clinical providers 
with a simplified overview of the structure, classification, and metabolism of lipids. 
This chapter will serve as a quick and illustrated reference to the reader of this book, 
Dyslipidemia, thus facilitating the understanding of the other book chapters.
2. Classification of lipids
There are three types of lipids:
Simple lipids such as oil and waxes.
Complex lipids such as phospholipids, glycolipids, and lipoproteins.
Derived lipids such as steroid hormones and lipid-soluble vitamins.
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3. Saturated and unsaturated fatty acids
Saturated fatty acids are those containing no double bonds such as acetic 
(CH3▬COOH) and palmitic acid (Figure 1).
Unsaturated fatty acids contain one or more double bonds and are divided into 
three categories: Monounsaturated (one double bond), polyunsaturated (two 
or more double bonds), and eicosanoids (derived from 20 carbons = eicosa) that 
include prostaglandins, thromboxanes, and leukotrienes.
4. Cis and trans bonds
Cis and trans bonds are isomers of fatty acids (Figure 2); nearly, all naturally 
occurring bonds are in cis configuration. Trans fatty acids are the results of partial 
hydrogenation, a process that is used to create solidified products such as mar-
garine. Trans fatty acids are proinflammatory, increase LDL and decrease HDL-
cholesterol, and increase risk for obesity, diabetes, and CVD. These deleterious 
effects of trans fats prompted the FDA to ban the production of partially hydroge-
nated oils in June 2018. Figure 2 illustrates how trans fats can stack neatly, one on 
top of the other, to create dense solid fats.
5. Overview of lipoprotein structure, function, and metabolism
Lipids are insoluble in water and are transported in the plasma (or extracellular 
fluids) by lipoproteins. These lipoproteins have, in their basic structure, a lipid core 
to be transported (triacylglycerols (TAG), phospholipids, and cholesterol esters). A 
hydrophilic layer in which apolipoproteins are embedded thus provides structural 
stability as well as identity for each type of the lipoprotein.
Figure 2. 
Cis- and trans-oleic acid.
Figure 1. 
Saturated and unsaturated fatty acids.
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There are five major types of lipoprotein (Figure 3), classified based on their 
density (hence their size) from ultra-low-density lipoprotein (ULDL = chylomi-
crons) to very-low-density lipoprotein (VLDL), intermediate-density lipoproteins 
(IDL), and high-density lipoproteins (HDL). Chylomicrons (CM) are the largest in 
diameter with the lowest density and the highest TAG content.
Lipoprotein lipase is an enzyme that cleaves VLDLs and TAGs. TAGs are cleaved 
into free fatty acids and glycerol. Fatty acids eventually undergo beta-oxidation, 
and their energy is used by the heart and skeletal muscles. In the blood, free fatty 
acids are bound to albumin.
6. Exogenous (intestinal) lipid transport pathway
CM, formed in the intestinal epithelial cells (enterocytes), are the lipoproteins 
involved in the transport of exogenous (dietary) lipids from the intestine to the 
lymphatic system into the circulation through the exogenous lipid metabolism 
pathway (Figure 3). These CM contain cholesterol esters (CE) and TAG, formed by 
re-esterification of FFA, and are carried to the peripheral tissues including muscles 
and adipose tissues. By the action of activated LPL, FFA are released and undergo 
beta-oxidation to be used as energy source or stored as fat in the adipose tissues.  
Figure 3. 
Lipid transport and storage.
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CM also, through the action of cholesterol ester transfer protein (CETP), acquire 
CE from HDL in exchange of TAG. Furthermore, CM in the lymphatic system 
exchange apo A-I and apo A-II for apo C and E from HDL. Apo C is required for the 
activation of the LPL, and apo E is required for the recognition of the CM remnants 
by the liver’s receptors (Figure 3).
7. Endogenous lipid transport pathway
TAG and cholesterol from CM catabolism (remnants) are endogenously pro-
duced in the liver and are secreted in VLDL that contains apo B-100 (Figure 3). 
Similar to the process described above with CM, apo C and apo E are acquired 
from HDL where apo C activates LPL that catalyzes the hydrolysis of TG in VLDL 
producing FFA that are taken up by the muscles for energy production or stored 
in the adipose tissues. And again, as with CM, through the action of CETP, VLDL 
exchange cholesterol for TAG with HDL resulting in the formation of IDL which 
can be taken up by the liver via the apo E/remnant receptor or further reduced by 
hepatic lipase into LDL.
LDL contains only one apoprotein (B-100) and is taken up by the liver through 
LDL receptors with approximately one-third utilized by peripheral cells for mem-
brane formation and steroidogenesis.
8. Reverse cholesterol transport pathway
This process involves the mobilization of cholesterol from the plasma mem-
branes of cells along the arterial walls and the delivery of the cholesterol to the 
liver in the form of cholesterol esters (CE), thus reducing cholesterol levels in the 
periphery and thereby reducing inflammation as well as atherosclerosis.
In the macrophages of the vessel wall, CEs are hydrolyzed via cholesterol 
ester hydrolase (CEH), thereby releasing free cholesterol. This free cholesterol is 
transported outside the macrophages via adenosine triphosphate-binding cassette 
transporter A1 (ABCA1) to apolipoprotein A1, forming nascent pre-β HDL. The 
free cholesterol is then esterified into CEs via lecithin-cholesterol acyltransferase 
(LCAT), and the nascent pre-β-HDL then becomes mature α-HDL which converts 
into mature α-HDL subtypes, α-HDL2 and α-HDL3. This process occurs in the ves-
sel walls as well as in the plasma and is mediated by LCAT as well as hepatic lipase 
(HL) and endothelial lipase (EL). Mature α-HDL2 and α-HDL3 continue to acquire 
free cholesterol delivered from inside the cells via ABCG1, therefore increasing the 
amount of cholesterol carried to the liver via the CE-rich α-HDL via either direct or 
indirect pathways (Figure 4).
In the direct hepatic cholesterol uptake pathway, CE-rich α-HDL binds to 
scavenger receptor B1 (SR B1) that recognizes Apo A1, and CEs are taken by hepa-
tocytes and excreted in bile. In the indirect hepatic cholesterol uptake pathway, 
CE-rich α-HDL exchanges CE for TAG from the TAG-rich LAD and VLDL particles, 
a process that is facilitated by CETP, thereby forming a TAG-rich HDL and CE-rich 
LDL and VLDL. CEs are then taken by hepatocytes via LDL receptors, catabolized, 
and also excreted in the bile, as with the direct pathway.
The processes described above are well regulated in healthy states and are quite 
abnormal in dyslipidemia, leading to excess CVD as well as other disorders such as 
nonalcoholic fatty liver disease (NAFLD), among others.
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Certain disease states interfere with lipid transport pathways, leading to serious 
disorders. For example, in diabetes mellitus, relative insulin resistance causes under-
utilization of VLDLs and chylomicrons, eventually leading to hypertriacylglycerolemia 
and increased small-density LDLs which promotes atherosclerosis [8]. Among many 
other roles, insulin inhibits the release of free fatty acids (FFA) from the adipose 
tissues and suppresses hepatic VLDL secretion into the circulation. These mechanisms 
come into play in the role of diabetes as a risk factor for CVD including stroke [8].
Furthermore, the inability to suppress VLDL-triglyceride kinetics has been 
implicated in the pathogenesis of nonalcoholic fatty liver disease [9], a serious com-
plication that leads to CVD, cancer, and liver fibrosis and increases mortality [10].
9. In conclusion
In this short introductory chapter, we provided a brief overview of lipid metabo-
lism highlighting the role of lipids as CVD risk factors, the various types of lipid 
structure and function as well as the exogenous (intestinal), and the endogenous 
lipid transport pathways through which fats are transported from the intestines 
and the liver, respectively, to the peripheral tissues. We also highlighted in some 
detail the reverse cholesterol transfer pathway via which cholesterol, in the form of 
cholesterol esters, are transported from the blood vessel walls and other tissues back 
to the liver for excretion in the bile.
Figure 4. 
Reverse cholesterol transport pathway. C, cholesterol; CE, cholesteryl ester; LCAT, lecithin cholesterol ethyl 
transferase; PL, phospholipid; ApoA-1, apolipoprotein A-1.
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